ARCHIVES

Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

NCI Cooperative Group Clinical Trials Approved

October 30, 2009

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

Public Health Service: Scientific Papers Become “Deliverables” In Own RFP

October 3, 1997

Early, Short Course Of Hormonal Therapy May Allow Patients To Live Longer

January 25, 2008

In Brief: Deisseroth Leaves M.D. Anderson To Head Yale’s Oncology, Gene Therapy Programs

September 15, 1995